3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neurofibromatosis 1
9
Breast Neoplasms
5
Neurofibroma, Plexiform
4
Lung Neoplasms
4
Triple Negative Breast Neoplasms
3
Neurofibrosarcoma
3
Thyroid Neoplasms
2
Neoplasms
2
Melanoma
2
Gallbladder Neoplasms
2
Uveal Melanoma
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Sarcoma, Kaposi
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Non-small Cell Lung Cancer Metastatic
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Meningioma
1
Liver Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Glioma
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
AZD 6244
×
Clear all
NCT01242605
2016-05-13
ABC-04
University College, London
Phase 1
Completed
13 enrolled